Evidence map›Paper›PMID 40185688›Full record

ArticleJournal of industrial microbiology & biotechnology2024

Exploration of alternative microfiltration modalities for the harvest and clarification of diverse recombinant proteins from high-density E. coli culture and lysate using hollow fibre, flat sheet cassette, and vibro membrane filtration technologies.

Jennifer Reid, Joyce Ni, Airong Chen, Patricia Gomes, Andrew Szto, Analyn Yu, Angela Luo, Belinda Kong, Calvin Adams, Neveathan Jeyachandran and 4 more

Abstract read
In one paragraph

Article in Journal of industrial microbiology & biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jennifer ReidGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.ORCID 0000-0002-7046-5271
Joyce NiGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.
Airong ChenGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.
Patricia GomesGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.
Andrew SztoGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.
Analyn YuGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.
Angela LuoGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.
Belinda KongGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.
Calvin AdamsGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.
Neveathan JeyachandranGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.
Anumta AmirGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.ORCID 0009-0001-5599-1927
Xavier TeixeiraGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Marcy-l'Étoile, 69280, France.
Tao YuanGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Toronto M2R 3T4 ON, Canada.ORCID 0009-0006-9530-207X
Cédric CharretierGlobal Bioprocess Development - Drug Substance Development, Sanofi Vaccines, Marcy-l'Étoile, 69280, France.

Funding

Sanofi Vaccines
6 · The paper itself

Abstract

Industrial bioprocess optimization has significantly increased the productivity of biomass and biologics in upstream production. Such process improvement in fermentation often translates to challenges in recovering intracellularly expressed recombinant proteins due to increased matrix complexity, resulting in a higher performance burden in midstream. Tangential flow filtration (TFF) is a popular industry standard for buffer exchange and protein separation from cellular debris. However, due to variations in the physicochemical properties of recombinant proteins, solutions for E. coli-based protein clarification remain challenging and often necessitate extensive exploration and process optimization. With growing options in filtration-based technologies, the identification of a near-universal clarification platform is desirable to accelerate bioprocess development overall. In this study, three TFF modalities, hollow fibre (HF), flat-sheet cassette (CAS), and vibro membrane filtration (VMF), were assessed in parallel to evaluate their clarification performance for three E. coli recombinant proteins with different biochemical properties. Reverse phase liquid chromatography data showed target protein recovery was uniformly higher for VMF than HF at equivalent loading. Cell density and lysate protein load were comparable for HF and VMF, and lower for CAS. These results support the choice of VMF and HF as easily optimized and operated TFF modalities for clarification of recombinant protein from complex crude bacterial matrix, where either can be efficiently performed with ease and minimum supervision. Both TFF applications were successfully demonstrated in primary cell harvest, cell wash and cell lysate clarification, for E. coli-based recombinant proteins. ONE-SENTENCE SUMMARY: High-density E. coli microfiltration and lysate clarification were tested for three diverse recombinant proteins, where hollow fibre and vibro membrane filtration outperformed flat sheet cassette in terms of process time, suspended solid loading, and target protein recovery.

Indexed as

Escherichia coliFiltrationRecombinant ProteinsFermentationRecombinant ProteinsBioprocessingClarificationE. coliFermentationMidstream

Identifiers

PMID40185688
PMCPMC12022607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.